Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 166, Issue 3, Pages 336-351
Publisher
Wiley
Online
2014-05-19
DOI
10.1111/bjh.12945
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma.
- (2017) D. S. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases
- (2014) Ryo Nasu et al. ANNALS OF HEMATOLOGY
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
- (2014) Sharmila Mallya et al. PLoS One
- Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
- (2014) Terence O'Reilly et al. Translational Oncology
- Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab
- (2013) Zi-Zhen Xu et al. ANNALS OF HEMATOLOGY
- Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
- (2013) Kurt G. Pike et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study
- (2013) Ágnes Márk et al. BMC CANCER
- A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
- (2013) Mathias Witzens-Harig et al. BMC CANCER
- Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma
- (2013) Anja Müller et al. INTERNATIONAL JOURNAL OF CANCER
- Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
- (2013) Li Dong et al. Journal of Hematology & Oncology
- Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
- (2013) Kerstin Kampa-Schittenhelm et al. Molecular Cancer
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
- (2012) B. Markman et al. ANNALS OF ONCOLOGY
- Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
- (2012) Z. Zeng et al. BLOOD
- Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer
- (2012) Haiyan Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
- (2012) A Naing et al. BRITISH JOURNAL OF CANCER
- Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1
- (2012) Chuanbing Zang et al. CANCER LETTERS
- Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
- (2012) A. M. Petrich et al. CLINICAL CANCER RESEARCH
- NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy
- (2012) Monica Civallero et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
- (2012) C. Renner et al. HAEMATOLOGICA
- Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
- (2012) J. A. Barnes et al. HAEMATOLOGICA
- The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
- (2012) Bao Hoang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
- (2012) M R Janes et al. LEUKEMIA
- The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
- (2012) Areumnuri Kim et al. LEUKEMIA RESEARCH
- Treatment of Older Patients with Mantle-Cell Lymphoma
- (2012) H.C. Kluin-Nelemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma
- (2011) Philipp Baumann et al. ANTI-CANCER DRUGS
- Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
- (2011) M. Gupta et al. BLOOD
- Defining the role of TORC1/2 in multiple myeloma
- (2011) P. Maiso et al. BLOOD
- Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
- (2011) J. K. Altman et al. CLINICAL CANCER RESEARCH
- The Pim Kinases: New Targets for Drug Development
- (2011) Ronan Swords et al. CURRENT DRUG TARGETS
- mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused
- (2011) Ismael Bracho-Valdés et al. IUBMB LIFE
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
- (2011) Stephen M Ansell et al. LANCET ONCOLOGY
- The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
- (2011) L Willems et al. LEUKEMIA
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
- (2011) Michal Marzec et al. PLoS One
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells
- (2010) Patrizia Sini et al. Autophagy
- Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
- (2010) K. Yu et al. CANCER RESEARCH
- Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia
- (2010) Irene M. Ghobrial et al. JOURNAL OF CLINICAL ONCOLOGY
- Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium
- (2010) Sonali M. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
- (2010) Shomit Sengupta et al. MOLECULAR CELL
- Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
- (2010) C A Sparks et al. ONCOGENE
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
- (2010) Nathalie Carayol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia
- (2009) A. M. Roccaro et al. BLOOD
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
- (2009) M. Gupta et al. BLOOD
- Signaling Events Downstream of Mammalian Target of Rapamycin Complex 2 Are Attenuated in Cells and Tumors Deficient for the Tuberous Sclerosis Complex Tumor Suppressors
- (2009) J. Huang et al. CANCER RESEARCH
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- mTOR and cancer: many loops in one pathway
- (2009) Alejo Efeyan et al. CURRENT OPINION IN CELL BIOLOGY
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
- (2008) Thomas Decker et al. ANNALS OF HEMATOLOGY
- Sirolimus, Tacrolimus, and Low-Dose Methotrexate as Graft-versus-Host Disease Prophylaxis in Related and Unrelated Donor Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
- (2008) Edwin P. Alyea et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
- (2008) J. Dal Col et al. BLOOD
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
- (2008) C. H. Geisler et al. BLOOD
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
- Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma
- (2008) Victor Y. Yazbeck et al. EXPERIMENTAL HEMATOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
- (2008) J A McCubrey et al. LEUKEMIA
- Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination
- (2008) Anna Åleskog et al. LEUKEMIA & LYMPHOMA
- Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma
- (2008) Saranya Chumsri et al. LEUKEMIA & LYMPHOMA
- The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2
- (2008) J. Huang et al. MOLECULAR AND CELLULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search